TetracosactrinSynacthen
Recommended NeurologyRestrictedNot applicable line 💬 consumer voice
Hypsarrhythmia and/or infantile spasms.
1
Submissions
2017–17
On the record
—
ICER range
Not modelled
Cost basis
Decision on record
- Meeting Nov 2017 Recommended Hypsarrhythmia and/or infantile spasms
Access path
- TGA registered · Synacthen
TGA label narrower than the PBS population
- Nov 2017Recommended · restricted
- PBS listing · Restricted
RecommendedDeferredNot recommended
From the public summary
PBAC outcome
5.1 The PBAC recommended the amendment of the current unrestricted benefit to a Restricted Benefit for use in patients with hypsarrhythmia and/or infantile spasms, noting this is a small patient group. 2PSD · Nov 2017
Cost-effectiveness
Minor submission with no economic evaluation; no ICER calculated.
Decision context
PopulationPatients with hypsarrhythmia and/or infantile spasms.
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2017 | Recommended · restricted | — | — | Other |
Consumer voice
No consumer comments were received for this item.
The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Regulatory · TGA
Label narrower than PBS population — PBAC excluded acute exacerbations in multiple sclerosis; approved only hypsarrhythmia and/or infantile spasms.